If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIQE Regulatory News (IQE)

Share Price Information for IQE (IQE)

Share Price is delayed by 15 minutes
Get Live Data
44.85    2.85 (6.79%)
Bid:
43.85
Ask:
44.35
Spread: 0.50 (1.14%)
Market Cap: £596.97m
IQE Live PriceLast checked at - London Stock Exchange

Intraday IQE Share Chart

Post Close Trading Update

25 Jan 2019 07:00



Post Close Trading Update

IQE plc

Cardiff, UK. 25th January 2019: IQE plc (AIM: IQE; "IQE", the “Company” or the "Group"), the leading global supplier of advanced wafer products and materials solutions to the semiconductor industry, provides the following post close trading update.

IQE expects to deliver revenues of not less than £156m for FY 2018 (FY 2017 £154.5m) and Adjusted EBITDA of at least £27.5m (FY 2017 £37.0m). Net Cash at 31 December 2018 was £20.8m (31 December 2017 £45.6m). On 24 January 2019, the Company agreed a new $35m multi-currency revolving credit facility (the “Facility”), provided by HSBC and which is secured over the assets of IQE. The Facility has a three-year term and an interest rate margin of between 1.45 and 1.95 per cent per annum over LIBOR on any drawn balances. The Facility is undrawn.

As previously announced, the Company is closing its facility in New Jersey (“NJ”) in order to consolidate its US based GaN manufacturing capacity in its existing Massachusetts (“MA”) facility. The cost of the NJ closure is estimated to be £3.35m, of which £1.2m will comprise the cash costs of severance and reactor decommissioning, with £2.15m of non-cash impairments. These costs will be an exceptional charge in the FY 2018 accounts. IQE expects to achieve annual operating cost savings of approximately £3m per annum, post the closure.

The Company also expects to incur an additional exceptional charge of approximately £4.5m, relating to an onerous lease accounting provision for the period through to the end of the lease in Q2 2022, for the unused and unlet space in its Singapore facility. This exceptional provision has no cash impact.

The company reiterates 2019 and longer term guidance and will publish its full year-end results on 20th March 2019.

Dr Drew Nelson, Chief Executive of IQE, said:

“It is of course very disappointing that a substantial inventory correction in the first half of 2018 and the sudden disruption in a significant supply chain and short-term demand for VCSEL wafers in November materially impacted our expected 2018 revenues and profitability. However, the position and prospects of IQE will not be defined by our 2018 financial results which were delivered with none of the benefits of the investment programs which are now nearing completion.

"By the end of H1 2019 we will have completed a significant two-year investment program across our global operations, commissioning our new mega-foundry in Newport which is dedicated to photonics, installing additional wireless capacity in Taiwan, expanding our GaN capacity in MA and Infrared capacity in Milton Keynes. In addition, we have made a considerable investment in engaging with more than 25 VCSEL chip companies underscoring IQE’s exceptional leadership position in the emerging VCSEL supply chains based on our technical excellence, proven ability to ramp and dedicated commitment to install capacity. We will bring additional photonics capacity into production in Phase 1 (first 10 reactors) in the new Newport foundry during H1 2019, with 12 companies already actively qualifying the new facility.

"The investment we have made in rationalisation, capacity and new products and the opportunity that this has created will deliver strong performance across our wireless, photonics and infra-red business units in the key sector areas of sensing, connectivity and energy, leading to margin expansion, increasing free cash flow and profitability in 2019 and beyond”.

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

GLOSSARY OF TERMSVCSEL......................... Vertical Cavity Surface Emitting Laser GaN............................. Gallium NitrideAdjusted EBITDA……. EBITDA after adjusting for the impact of one-off, non-cash and non-operational items

CONTACTS:

IQE plc Godfrey Ainsworth Drew Nelson Chris Meadows +44 (0) 29 2083 9400
Canaccord Genuity (Nomad and Joint Broker) Simon Bridges Richard Andrews + 44 (0) 20 7523 8000
Peel Hunt (Joint Broker) Edward Knight Nick Prowting+44 (0) 20 7418 8900

ABOUT IQE

http://iqep.com IQE is the leading global supplier of advanced semiconductor wafers that enable a diverse range of applications, supported by an innovative outsourced foundry services portfolio that allows the Group to provide a 'one stop shop' for the wafer needs of the world's leading semiconductor manufacturers. IQE uses advanced crystal growth technology (epitaxy) to manufacture and supply bespoke semiconductor wafers 'epi-wafers' to the major chip manufacturing companies, who then use these wafers to make the chips which form the key components of virtually all high technology systems. IQE is unique in being able to supply wafers using all of the leading crystal growth technology platforms. IQE's products are found in many leading-edge consumer, communication, computing and industrial applications, including a complete range of wafer products for the wireless industry, such as smartphones and wireless infrastructure, Wi-Fi, base stations, and satellite communications; optical communications, optical storage, printing, thermal imagers, leading-edge medical technologies, automotive and aerospace technologies, a variety of advanced silicon based systems and high efficiency concentrator photovoltaic (CPV) solar cells. IQE operates multiple manufacturing and R&D facilities worldwide.


Date   Source Headline
1st Mar 20187:00 amRNSIQE wins place at GREAT innovation Festival
22nd Feb 20187:00 amRNSCSC announces joint programme with partner ICS Ltd
8th Feb 201812:07 pmRNSSecond Price Monitoring Extn
8th Feb 201812:02 pmRNSPrice Monitoring Extension
21st Dec 20177:00 amRNSIQE Group expands IP portfolio
20th Jul 20174:35 pmRNSPrice Monitoring Extension
12th Jun 20177:00 amRNSCardiff hosts international VCSEL technology event
1st Jun 20177:00 amRNSIQE wins 2017 Raytheon Supplier Award
29th Nov 20168:04 amRNSIQE and BLUGLASS announce strategic partnership
17th May 20167:00 amRNSIQE news update from CS-Mantech conference
16th May 20167:00 amRNSIQE Joins imec's GaN-on-Si Program
19th Apr 20167:16 amRNSIQE joins EUR15m project
17th Feb 20167:05 amRNSProfessor Colin Whitehouse appointed as CSC Chair
8th Jan 20167:01 amRNSCompound Semiconductor Catapult Centre announced
7th Oct 20157:00 amRNSIQE's GaN on Si achieves breakthrough results
30th Jul 201511:00 amRNSIQE key partner in US Integrated Photonics program
21st Apr 20157:00 amRNSIncreasing demand for IQE's Infrared products
31st Mar 20147:00 amRNS200mm GaN on Silicon for next generation CMOS
19th Mar 20147:00 amRNSIQE delivers 150mm (6") VCSEL epiwafers
13th Mar 20147:00 amRNSIQE's VCSEL wafers enable record performance
11th Mar 20147:20 amRNSPresentation at OFC
22nd Aug 20137:00 amRNSIQE reports new CPV cell efficiency
5th Jun 20132:22 pmRNSMerger Update
8th Mar 20133:00 pmRNSMerger Update
8th Jan 20138:39 amRNSStatement regarding press articles
31st Jul 20123:54 pmRNSDirectorate Change
10th Apr 20125:11 pmRNSDirector Dealings
27th Mar 20122:00 pmRNSPartnership Agreement
8th Feb 20124:10 pmRNSCompletion of Placing
17th Feb 20103:56 pmRNSNominated Adviser Change of Name
7th Aug 20094:42 pmRNSHolding(s) in Company
7th Aug 20094:30 pmRNSBondholders meeting
7th Aug 20093:51 pmRNSDirector Dealing in Shares
12th Jun 20081:42 pmRNSAdditional Listing
15th Apr 20087:01 amRNSAdditional Listing
7th Apr 200812:14 pmRNSDirector/PDMR Shareholding
28th Mar 200811:52 amRNSDirector/PDMR Shareholding
19th Mar 20087:00 amRNSDirector/PDMR Shareholding
17th Mar 20081:00 pmRNSContract Win
17th Mar 20087:01 amRNSFinal Results
28th Feb 20083:27 pmRNSHolding(s) in Company
19th Feb 20088:30 amRNSNotice of Results
25th Jan 20087:00 amRNSBank Facilities
17th Jan 20087:00 amRNSTrading Update
16th Jan 200811:15 amRNSBroker Appointment
15th Jan 200812:12 pmRNSDirector/PDMR Shareholding
9th Jan 20084:26 pmRNSAdditional Listing
7th Jan 20087:00 amRNSDirector/PDMR Shareholding
4th Jan 200812:46 pmRNSHolding(s) in Company
19th Dec 20077:30 amRNSAdditional Listing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.